
Experts share insights on the latest innovations in multiple sclerosis research, in highlights from a recent State of the Science SummitTM, presented by Neurology Live®.
Experts share insights on the latest innovations in multiple sclerosis research, in highlights from a recent State of the Science SummitTM, presented by Neurology Live®.
Advice to community physicians and neurologists who play a role in caring for patients with multiple sclerosis in community practices on optimizing therapy with high-efficacy and newer treatment options.
Gaps in care that neurologists experience when treating patients with relapsing-remitting multiple sclerosis and considerations for recommending lifestyle modifications to help manage symptoms.
Exciting strategies and biomarkers being investigated to improve the evaluation and treatment of patients with relapsing-remitting multiple sclerosis.
Drs Patricia K. Coyle and Robert Fox comment on approaching multiple sclerosis relapses as early as possible with high-efficacy therapy.
Factors that may warrant a switch in therapy to treat relapsing-remitting multiple sclerosis.
Recommendations regarding how to monitor patients who receive therapy for relapsing-remitting multiple sclerosis and to conduct repeat imaging assessments appropriately.
Factors that impact treatment selection for a 25-year-old woman who presents with relapsing multiple sclerosis, including the patient’s interest in becoming pregnant.
Clyde E. Markowitz, MD, reacts to how he would manage a 25-year-old woman who presents with 2 weeks of progressive left-sided monocular vision loss and pain with eye movement, but reports no other symptoms or significant history.
Important considerations regarding the use of anti-CD20 therapies such as ofatumumab to treat relapsing multiple sclerosis during the COVID-19 pandemic and strategies that can help neurologists talk with patients about drug use and COVID-19 vaccinations.
The rationale for treating patients with relapsing multiple sclerosis with ofatumumab based on data revealed by the ASCLEPIOS I and ASCLEPIOS II trials.
Implications for initiating treatment with a high-efficacy therapy for a 35-year-old man who presents with progressive numbness and weakness in his left arm and leg.
Impressions of exam results and the prognosis for a 35-year-old man who presents with progressive numbness and weakness in his left arm and leg.
An overview of high-efficacy therapies available to treat patients with relapsing-remitting multiple sclerosis.
Robert Fox, MD, of the Cleveland Clinic, comments on the advantage of starting treatment with a high-efficacy therapy for relapsing-remitting multiple sclerosis and explains his approach to counseling patients when selecting treatment.
Dr Patricia K. Coyle, of the Stony Brook Neurosciences Institute, comments on her approach to selecting first-line therapy to treat relapsing-remitting multiple sclerosis, explaining how she selects between a lower-risk or high-efficacy therapy.
The rationale for initiating aggressive therapy early on to treat patients who present with relapsing-remitting multiple sclerosis.
An overview of the clinical subtypes of multiple sclerosis and factors that help neurologists distinguish between each type for an appropriate diagnosis.
Clyde E. Markowitz, MD, comments on the growing role of magnetic resonance imaging to help diagnose multiple sclerosis and highlights characteristics of lesions he looks at during a diagnostic evaluation.
Patricia K. Coyle, MD, highlights revisions to the McDonald diagnostic criteria for multiple sclerosis and emphasizes why health care professionals need to start referring to the criteria in a more standard fashion.
Published: August 29th 2025 | Updated: September 2nd 2025
Published: July 28th 2025 | Updated: July 30th 2025
Published: May 14th 2025 | Updated: May 16th 2025
Published: May 12th 2025 | Updated: May 13th 2025
Published: March 27th 2025 | Updated: March 28th 2025
Published: March 4th 2025 | Updated: March 19th 2025